IGFBP2 and breast carcinoma: Also, in breast cancer, IGFBP‐2 exerts malignant potential, and again, this depends on the RGD‐motif but involves regulation of estrogen receptors as demonstrated by the Perks laboratory (Foulstone et al., 2013).